Bharat Biotech

Bharat Biotech News

Why approval for Bharat Biotech’s iNCOVACC, world’s first intranasal COVID vaccine, is a big deal
Explainers

Why approval for Bharat Biotech’s iNCOVACC, world’s first intranasal COVID vaccine, is a big deal

Bharat Biotech says iNCOVACC has several advantages including being non-invasive and needle-free. Trained healthcare workers are not required to administer it, and it can eliminate needle-associated risks such as injuries and infections

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval
Health

Bharat Biotech’s Intranasal COVID-19 vaccine gets CDSCO approval

iNCOVACC is the world’s first Intranasal vaccine for COVID to receive approval for the primary 2-dose schedule, and heterologous booster dose

Nearly 50 million doses of Covaxin expected to expire in early 2023 due to low product demand
Business

Nearly 50 million doses of Covaxin expected to expire in early 2023 due to low product demand

Bharat Biotech has more than 200 million doses of Covaxin in bulk form and approximately 50 million doses in vials ready to use. Due to lack of product demand, production stoppage of Covaxin was initiated several months ago, earlier this year, say sources

Bharat Biotech gets nod for India's first nasal COVID vaccine: Why this is a potential game-changer
Explainers

Bharat Biotech gets nod for India's first nasal COVID vaccine: Why this is a potential game-changer

Bharat Biotech says the vaccine is easy to administer as it is non-invasive and does not require trained healthcare workers. It also eliminates needle-associated risks such as injuries and infections and is scalable when it comes to manufacturing

COVID-19: India's first nasal vaccine by Bharat Biotech gets drug panel's nod for 'restricted use'
Health

COVID-19: India's first nasal vaccine by Bharat Biotech gets drug panel's nod for 'restricted use'

The Central Drugs Standard Control Organisation has approved the vaccine for primary immunisation against COVID-19 in the above 18 age group for 'restricted use in an emergency situation'

Bharat Biotech's Rotavac introduced in Nigeria to immunise children from diarrhoea
World

Bharat Biotech's Rotavac introduced in Nigeria to immunise children from diarrhoea

Nigeria currently accounts for 14 per cent of all childhood rotavirus deaths globally, making it the country with the second-highest number of rotavirus deaths in the world

Nasal vaccine: A futuristic intervention in immunisation drive
Health

Nasal vaccine: A futuristic intervention in immunisation drive

Nasal vaccines are easier to administer, especially it would be a great relief for people who are afraid of needles and for children and the elderly population as it is non-invasive

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine
Health

Bharat Biotech completes clinical development for phase III trials, booster doses for BBV154 intranasal COVID vaccine

BBV154 has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that helps mass immunisation protect from emerging concern variants

200 crore vaccinations: How India under Narendra Modi scripted Covid success story
India

200 crore vaccinations: How India under Narendra Modi scripted Covid success story

The country crossed a record 200 crore Covid-19 vaccinations on 17 July 2022 within barely 18 months of launching this exercise on 16 January last year

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech
Health

Covaxin safe, well-tolerated in 2-18 years age-group, announces Bharat Biotech

The clinical trial conducted in the paediatric population between June 2021 to September 2021 has shown safety, less reactogenic, and robust immunogenicity

Germany to recognise Bharat Biotech's COVID-19 vaccine Covaxin for travel from 1 June
India

Germany to recognise Bharat Biotech's COVID-19 vaccine Covaxin for travel from 1 June

In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin

Bharat Biotech consortium gets Rs 149 crore funding to develop 'variant proof' COVID vaccine
Health

Bharat Biotech consortium gets Rs 149 crore funding to develop 'variant proof' COVID vaccine

Bharat Biotech Chairman Krishna Ella said while the current vaccines are safe and effective against presently known variants, it is imperative that there is a focus on innovation for multi-epitope vaccines, where a single vaccine can protect against all future variants

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group
India

COVID-19: Bharat Biotech seeks DCGI's permission to conduct Covaxin booster trials in 2-18 age group

The company has already conducted trials in the age group of 2-18 for two doses of Covaxin

Bharat Biotech must address WHO's Covaxin supply suspension to avoid EUL cancellation: MEA
Health

Bharat Biotech must address WHO's Covaxin supply suspension to avoid EUL cancellation: MEA

Following an inspection of the Bharat Biotech premises on 14 March for Covaxin's EUL, WHO announced the suspension of the vaccine's supply owing to deficiencies in good manufacturing practices

Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12
India

Corbevax, Biological E's COVID-19 vaccine, gets DCGI's emergency use authorisation for children aged 5-12

The DCGI has also given restricted emergency use authorisation to Covaxin, manufactured by Hyderabad based pharmaceutical company - Bharat Biotech, for children between 6 and 12 years

DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years
India

DCGI clears Bharat Biotech's Covaxin for restricted emergency use in children aged 6-12 years

Bharat Biotech has been asked to submit safety data alongwith the data on adverse event with due analysis, every 15 days for the first two months and after that monthly data for up to five months

DCGI expert panel holds meet on recommendations to use Corbevax, Covaxin vaccines for 5-12 age group
Health

DCGI expert panel holds meet on recommendations to use Corbevax, Covaxin vaccines for 5-12 age group

India is currently administering two COVID-19 vaccines for children above 12

Explained: The measures that Bharat Biotech will take in response to WHO’s suspension of Covaxin
India

Explained: The measures that Bharat Biotech will take in response to WHO’s suspension of Covaxin

The WHO directed the Hyderabad-based company to upgrade its facilities to address deficiencies in good manufacturing practices. Bharat Biotech will temporarily slow down Covaxin’s production to focus on the job at hand

WHO suspends Bharat Biotech's Covaxin supply for UN procurement agencies citing 'deficiencies'
India

WHO suspends Bharat Biotech's Covaxin supply for UN procurement agencies citing 'deficiencies'

The international health body, however, maintained that data available on India’s first indigenous COVID-19 vaccine indicated that it was effective and there were no safety concerns

US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech
Health

US to evaluate Covaxin as COVID-19 vaccine candidate, announces Bharat Biotech

The FDA has lifted its clinical hold on Bharat Biotech's Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as Covaxin outside the United States